A composition for promoting keratinocyte proliferation and use thereof
By using a combination of ergothioneine, oligopeptide-1, and active ingredient A, the problem of slow proliferation of keratinocytes in vitro has been solved, resulting in improved cell proliferation rate and viability, making it suitable for keratinocyte culture and skin care products.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- ZHONGKE ORIENTAL CELL TECH CO LTD
- Filing Date
- 2022-11-25
- Publication Date
- 2026-07-21
AI Technical Summary
In existing technologies, the in vitro culture of keratinocytes has a slow proliferation rate and a limited number of passages, making it difficult to meet the needs of cell migration and repair experiments.
The composition employs ergothioneine, oligopeptide-1, and active ingredient A, which consists of sodium chloride, sodium dihydrogen phosphate, 1,2-hexanediol, fibronectin, serum albumin, polysorbate-80, capryloyl hydroxamic acid, ethylhexylglycerol, and glyceryl caprylate, to promote the proliferation of keratinocytes.
It significantly improves the proliferation rate and viability of keratinocytes and enhances their migration ability, making it suitable for preparing culture media, skin care products, and wound healing drugs.
Smart Images
Figure BDA0003964311320000071 
Figure BDA0003964311320000081 
Figure HDA0003964311330000011
Abstract
Description
Technical Field
[0001] This invention belongs to the field of pharmaceutical and cosmetic technology, specifically relating to a composition that promotes the proliferation of keratinocytes and its application. Background Technology
[0002] Human keratinocytes are typically isolated from the epidermis of juvenile foreskin or adult skin from single or aggregated donors. Representing the dominant cell type of the epidermis, keratinocytes form the outermost layer of the skin, comprising approximately 90% of its cells. They originate in the deepest layer of the epidermis, the basal layer, and migrate upwards to the last barrier layer of the skin, the stratum corneum. There, keratinocytes are found as anucleate, flattened, and highly keratinized squamous cells. During this process, they undergo morphological changes and begin producing keratin, cytokines, growth factors, interleukins, and complement factors. Keratinocyte differentiation is regulated by a variety of factors and epigenetic mechanisms. They play a crucial role in protection, forming a tight barrier that prevents foreign substances from entering the body while minimizing the loss of moisture, heat, and other components. These cells also have a structural role, forming tight bonds with other cells in the epidermis and maintaining them in their position. Furthermore, keratinocytes act as immunomodulators after skin injury. Normal human epidermal keratinocytes (NHEK) can be isolated from juvenile foreskin or from normal adult human tissues from various locations, including the face, breast, abdomen, and thigh. For research purposes, NHEK from a single donor or a pool of donors can be used. The concentration of nutrients in the culture is crucial for ensuring optimal conditions for keratinocyte proliferation and differentiation.
[0003] Although in vitro culture techniques for keratinocytes are well-established, resulting in rapid growth and high cell survival rates, they are also prone to aging and have a limited number of passages. At higher passage numbers, the proliferation rate slows down, which is unfavorable for experiments such as cell migration, cell proliferation, and cell repair. Therefore, it is necessary to develop a composition that promotes keratinocyte proliferation. Summary of the Invention
[0004] In order to overcome the shortcomings of the prior art, the first aspect of the present invention is to provide a composition that promotes the proliferation of keratinocytes.
[0005] A second aspect of the present invention is to provide a method for preparing the composition of the first aspect.
[0006] A third aspect of the present invention is to provide the application of the composition of the first aspect.
[0007] A fourth aspect of the present invention is to provide a product.
[0008] The fifth aspect of the present invention is to provide a method for culturing keratinocytes.
[0009] To achieve the above objectives, the technical solution adopted by the present invention is as follows:
[0010] In a first aspect, the present invention provides a composition for promoting the proliferation of keratinocytes, comprising: ergothioneine, oligopeptide-1, and active ingredient A;
[0011] The active ingredient A comprises: sodium chloride, sodium dihydrogen phosphate, 1,2-hexanediol, fibronectin, serum albumin, polysorbate-80, capryloyl hydroxamic acid, ethylhexylglycerin, and glyceryl caprylate.
[0012] Preferably, the mass ratio of ergothioneine, oligopeptide-1 and active ingredient A is 1:(5-18):(1-11); further, it is 1:(17 / 3-17):(5 / 3-10); even further, it is 1:(17 / 3-17):(8 / 3-10); and still further, it is 1:17:10.
[0013] Preferably, the active ingredient A comprises: sodium chloride, sodium dihydrogen phosphate, 1,2-hexanediol, fibronectin, serum albumin, polysorbate-80, capryloyl hydroxamic acid, ethylhexylglycerin, and glyceryl caprylate.
[0014] Preferably, the active ingredient A further comprises: water.
[0015] Preferably, the active ingredient A comprises the following components in weight percentage: sodium chloride 1.25-2.25%, sodium dihydrogen phosphate 0.35-0.75%, 1,2-hexanediol 0.25-0.5%, fibronectin 0.05-0.15%, serum albumin 0.02-0.08%, polysorbate-80 0.02-0.08%, capryloyl hydroxamic acid 0.02-0.08%, ethylhexylglycerin 0.02-0.08%, glyceryl caprylate 0.01-0.04%, and water 95-99%; more preferably, the active ingredient A comprises the following components in weight percentage: sodium chloride 1.75%, sodium dihydrogen phosphate 0.55%, 1,2-hexanediol 0.375%, fibronectin 0.1%, serum albumin 0.05%, polysorbate-80 0.05%, capryloyl hydroxamic acid 0.05%, ethylhexylglycerin 0.05%, glyceryl caprylate 0.025%, and water 97%.
[0016] A second aspect of the invention provides a method for preparing a composition similar to that of the first aspect, comprising mixing ergothioneine, oligopeptide-1, and active ingredient A.
[0017] A third aspect of the invention provides the use of the composition of the first aspect in the preparation of a product.
[0018] Preferably, the product comprises reagents, kits, culture media, skin care products, and pharmaceuticals.
[0019] Preferably, the reagents, kits, and culture media are used to promote the proliferation of keratinocytes.
[0020] Preferably, the skin care products include scalp care products, body care products, and cosmetics.
[0021] Preferably, the medicine is used for wound repair.
[0022] A fourth aspect of the invention provides a product comprising the composition of the first aspect of the invention.
[0023] Preferably, the product comprises reagents, kits, culture media, skin care products, and pharmaceuticals.
[0024] Preferably, the reagents, kits, and culture media are used to promote the proliferation of keratinocytes.
[0025] Preferably, the skin care products include scalp care products, body care products, and cosmetics.
[0026] Preferably, the medicine is used for wound repair.
[0027] Preferably, when the product is a culture medium, the product further comprises at least one of the following: glutamine, HEPES buffer, non-essential amino acids (NEAA), EGF (human epidermal growth factor), and basal culture medium.
[0028] Preferably, when the product is a culture medium, the culture medium comprises: the composition of the first aspect of the present invention, glutamine, HEPES buffer, non-essential amino acids (NEAA), EGF (human epidermal growth factor), and basal culture medium.
[0029] Preferably, when the product is a culture medium, the culture medium contains the following components in weight percentage: 2-3% of the composition of the first aspect of the present invention, 0.3-0.7% of glutamine, 0.1-0.2% of HEPES buffer, 0.01-0.05% of non-essential amino acids (NEAA), 0.01-0.05% of EGF (human epidermal growth factor), and 95-98% of basal culture medium.
[0030] Preferably, the basal culture medium comprises DMEM medium; further, it is high-glucose DMEM medium; and even further, it is high-glucose DMEM medium containing FBS.
[0031] Preferably, when the product is a skin care product and / or a pharmaceutical product, the product further comprises excipients.
[0032] Preferably, the excipients comprise at least one of the following: humectant, thickener, emulsifier, gelling agent, preservative, antioxidant, soothing agent, skin conditioner, pH regulator, moisturizer, chelating agent, fragrance, and water.
[0033] Preferably, the moisturizer comprises at least one of glycerin, propylene glycol, 1,3-butanediol, methylpropylene glycol, and sodium hyaluronate.
[0034] Preferably, the thickener comprises at least one of acrylate / C10-30 alkanol acrylate crosspolymer, carbomer, xanthan gum, hydroxyethyl cellulose, hydroxypropyl cellulose, and hydroxypropyl methyl cellulose.
[0035] Preferably, the emulsifier comprises at least one of sucrose stearate, cetyl palmitate, polyglycerol-3-methyl glucoside distearate, triterene PEG-20 ester, sorbitan olive oil ester, cetearyl olive oil ester, polyglycerol-6 stearate, glyceryl stearate, polyglycerol-6 behenate, stearyl alcohol polyether-21, and PEG-100 stearate.
[0036] Preferably, the gelling agent is a semi-solid, suspension system. The single-phase gelling agent comprises an organic polymer that is substantially uniformly distributed throughout the carrier liquid, generally aqueous, and preferably contains an alcohol and optionally an oil. The preferred "organic polymer," i.e., the gelling agent, can be a chemically cross-linked polymer such as a cross-linked acrylic polymer, for example, a "carbomer" family polymer, such as a carboxylated polyolefin, which is commercially available under the trademark Carbopol. In some embodiments, the preferred organic polymer can also be a hydrophilic polymer, such as polyethylene oxide, polyoxyethylene-polyoxypropylene copolymer, and polyvinyl alcohol; a cellulose polymer, such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, and methylcellulose; a gum, such as tragacanth gum and xanthan gum; sodium alginate; and gelatin. To prepare a uniform gel, a dispersant such as an alcohol or glycerol can be added, or the gelling agent can be dispersed by grinding, mechanical mixing, or stirring, or a combination thereof.
[0037] Preferably, the preservative comprises at least one of parabens, phenoxyethanol, chlorphenesin, sodium benzoate, potassium sorbate, phenethyl alcohol, and p-hydroxyacetophenone.
[0038] Preferably, the antioxidant comprises at least one of vitamin E, tea polyphenols, and resveratrol.
[0039] Preferably, the soothing agent contains at least one of chamomile extract and α-bisabolol.
[0040] Preferably, the skin conditioning agent contains at least one of dipotassium glycyrrhizate and allantoin.
[0041] Preferably, the alkalinity regulator comprises at least one of sodium hydroxide, triethanolamine, and arginine.
[0042] Preferably, the emollient comprises at least one of plant oils, animal oils, synthetic oils, and mineral oils.
[0043] Preferably, the chelating agent comprises at least one of EDTA-2NA and EDTA-4NA.
[0044] A fifth aspect of the present invention is to provide a method for culturing keratinocytes, comprising the steps of using the composition of the first aspect of the present invention and / or the culture medium of the fourth aspect of the present invention.
[0045] Preferably, the culture method includes the following steps: mixing keratinocytes with the culture medium from the four aspects of the present invention, and culturing them.
[0046] Preferably, the culture conditions are: 35-39℃, 4-6% CO2 culture for 30-100h.
[0047] The beneficial effects of this invention are:
[0048] This invention provides a composition comprising: ergothioneine, oligopeptide-1, and active ingredient A; said active ingredient A comprises: sodium chloride, sodium dihydrogen phosphate, 1,2-hexanediol, fibronectin, serum albumin, polysorbate-80, capryloyl hydroxamic acid, ethylhexylglycerin, and glyceryl caprylate; this composition has a synergistic effect in promoting cell proliferation and can be used to prepare reagents, kits, and culture media for culturing keratinocytes, as well as skin care products (scalp care products, body care products, and cosmetics) and wound healing medicines. Attached Figure Description
[0049] Figure 1 This is a statistical graph showing the effect of the compositions for promoting keratinocyte proliferation in Examples 1-3 and the substances for promoting keratinocyte proliferation in Comparative Examples 1-3 on relative migration distance. Detailed Implementation
[0050] The present invention will be further described in detail below with reference to specific embodiments and accompanying drawings.
[0051] It should be understood that these embodiments are for illustrative purposes only and are not intended to limit the scope of the invention.
[0052] Unless otherwise specified, the reagents, methods and equipment used in the following examples are conventional reagents, methods and equipment in this technical field.
[0053] Unless otherwise specified, all reagents and materials used in the following examples are commercially available.
[0054] In this example / comparative example, ergothioneine was purchased from Maclean's, catalog number: L864254-10mg; oligopeptide-1 was purchased from Nuvoline, catalog number: NFSW-090; active ingredient A consisted of the following components by weight percentage: sodium chloride 1.75%, sodium dihydrogen phosphate 0.55%, 1,2-hexanediol 0.375%, fibronectin 0.1%, serum albumin 0.05%, polysorbate-80 0.05%, capryloyl hydroxamic acid 0.05%, ethylhexylglycerin 0.05%, glyceryl caprylate 0.025%, water 97%; glutamine was purchased from Aladdin, catalog number L353976-25mg; and HEPES buffer was purchased from Cell Signaling. Technology, catalog number 44686S; Non-essential amino acid solution (NEAA), purchased from HARVEYBIO, catalog number NEAA; EGF (human epidermal growth factor), purchased from PrimeGene, catalog number 105-04B.
[0055] Ergothioneine is a rare natural chiral amino acid with unique cellular physiological protective functions, including scavenging free radicals, detoxification, maintaining DNA biosynthesis, normal cell growth, cellular immunity, anti-radiation, whitening, and anti-aging. Ergothioneine has broad application prospects in the food, cosmetics, functional food, and biopharmaceutical industries, and was included in the EU's list of new food resources in 2018.
[0056] Oligopeptide-1 is a polymer composed of glycine, histidine, and lysine. Oligopeptide-1 can effectively inhibit cell degeneration, enhance immune function, and reduce collagen loss.
[0057] Ergothioneine and oligopeptide 1 are both commonly used raw materials for antioxidant products.
[0058] Active ingredient A can enhance cell adhesion and promote cell keratinization.
[0059] Example 1: A composition that promotes keratinocyte proliferation
[0060] A composition for promoting keratinocyte proliferation, comprising ergothioneine, oligopeptide-1 and active ingredient A; wherein the mass ratio of ergothioneine, oligopeptide-1 and active ingredient A is 3:20:5.
[0061] The above-mentioned anti-inflammatory composition is prepared by mixing ergothioneine, oligopeptide-1 and active ingredient A.
[0062] Example 2: A composition that promotes keratinocyte proliferation
[0063] A composition for promoting keratinocyte proliferation, comprising ergothioneine, oligopeptide-1 and active ingredient A; wherein the mass ratio of ergothioneine, oligopeptide-1 and active ingredient A is 3:17:8.
[0064] The above-mentioned anti-inflammatory composition is prepared by mixing ergothioneine, oligopeptide-1 and active ingredient A.
[0065] Example 3: A composition that promotes keratinocyte proliferation
[0066] A composition for promoting keratinocyte proliferation, comprising ergothioneine, oligopeptide-1 and active ingredient A; wherein the mass ratio of ergothioneine, oligopeptide-1 and active ingredient A is 1:17:10.
[0067] The above-mentioned anti-inflammatory composition is prepared by mixing ergothioneine, oligopeptide-1 and active ingredient A.
[0068] Comparative Example 1: A substance that promotes keratinocyte proliferation
[0069] Ergothioneine is a substance that promotes the proliferation of keratinocytes.
[0070] Comparative Example 2: A substance that promotes keratinocyte proliferation
[0071] Oligopeptide-1 is a substance that promotes the proliferation of keratinocytes.
[0072] Comparative Example 3: A substance that promotes keratinocyte proliferation
[0073] A substance that promotes the proliferation of keratinocytes, is active ingredient A.
[0074] Effect Example
[0075] Experimental Operation
[0076] (1) Cell culture: Prepare stable keratinocytes (purchased from Beina Biotechnology, catalog number: BNCC340593), digest them with trypsin, and follow the 5×10⁻⁶ ppm rule. 5 The inoculum was seeded into 6-well plates at a rate of 2 mL per well. The plates were first cultured in high-glucose DMEM in an incubator (37°C, 5% CO2) for 2 h, then 10% serum was added, and the plates were incubated in an incubator (37°C, 5% CO2) for 24 h.
[0077] (2) Cell scratching: First, use a marker pen to draw evenly horizontal lines on the back of the 6-well plate, about 0.5-1 cm apart, through the wells. Use a pipette tip to draw the horizontal lines on the back of the plate, as perpendicular as possible (the pipette tip should be vertical and not tilted). Wash the cells three times with PBS to remove the scratched cells.
[0078] (3) Cell drug administration: The experiment included a solvent control group and a sample group, with three replicates in each group, as follows: After culturing cells seeded in 6-well plates for 24 hours, the supernatant was removed, and the cells were drugged into groups, with 2 mL administered to each well. The solvent control group received culture medium A (containing the following volume percentages: 0.5% glutamine, 0.15% HEPES buffer, 0.03% non-essential amino acid solution (NEAA), 0.03% EGF (human epidermal growth factor), and 99.29% high-glucose DMEM medium (containing 10% FBS)). The sample group received culture medium B (containing the following volume percentages: 0.5% glutamine, 0.15% HEPES buffer, 0.03% non-essential amino acid solution (NEAA), 0.03% EGF (human epidermal growth factor), and 99.29% high-glucose DMEM medium (containing 10% FBS)). FBS 96.49%, samples (compositions for promoting keratinocyte proliferation in Examples 1-3 and substances for promoting keratinocyte proliferation in Comparative Examples 1-3) 2.8%. After administration, the 6-well plates were placed in an incubator (37°C, 5% CO2) and cultured for 36 hours. (Glutamine, HEPES buffer, non-essential amino acid solution (NEAA), and EGF (human epidermal growth factor) in culture media A and B are maintenance culture components, not core or necessary components, and can be omitted during culture).
[0079] (3) Cell detection: ImageJ was used to detect the scratches; and trypsin digestion was used to collect cells, and the cell count (including the number of live cells and the total number of cells) was calculated using a microscope.
[0080] The results of cell scratch repair are shown in Tables 1, 2, 3, 4, and 5. Figure 1As shown: Compared with the solvent control group, the relative migration distance / cell number / cell viability of the sample groups (the compositions for promoting keratinocyte proliferation in Examples 1-3 and the substances for promoting keratinocyte proliferation in Comparative Examples 1-3) were all increased. In particular, under the same treatment concentration, the relative migration distance / cell number / cell viability of the compositions for promoting keratinocyte proliferation in Examples 1-3 were significantly higher than those of the substances for promoting keratinocyte proliferation in Comparative Examples 1-3; indicating that the components in the compositions for promoting keratinocyte proliferation provided in this application have a synergistic effect; especially, under the same treatment concentration, the compositions for promoting keratinocyte proliferation in Examples 2 and 3... The relative migration distance increase relative to the solvent control group (69 μm, 109 μm) was higher than the sum of the increases of each component (the substances promoting keratinocyte proliferation in Comparative Examples 1-3) relative to the solvent control group (57 μm) (having a similar effect in terms of cell number growth), further demonstrating that the components in the composition for promoting keratinocyte proliferation provided in this application have a synergistic effect; indicating that the composition provided in this application has an excellent effect on promoting keratinocyte proliferation and is non-cytotoxic, and can be used to prepare reagents, kits, culture media for culturing keratinocytes, skin care products (scalp care products, body care products and cosmetics), and wound repair medicines.
[0081] Table 1. Effects of the compositions promoting keratinocyte proliferation in Examples 1-3 and the substances promoting keratinocyte proliferation in Comparative Examples 1-3 on relative migration distance.
[0082] Relative migration distance (μm) after 36 hours P Value Solvent control group 51±3 / Comparative Example 1 55±4* 0.0422 Comparative Example 2 85±7* 0.0238 Example 1 101±11** 0.0037 Example 2 120±15** 0.0016 Example 3 160±20** 0.0006 Comparative Example 3 70±6* 0.0391
[0083] Note: When performing statistical analysis using the t-test method, the significance of each sample group compared with the solvent control group is indicated by *, p-value < 0.05 indicates *, and p-value < 0.01 indicates **.
[0084] Table 2. P-values between the effects of the compositions promoting keratinocyte proliferation in Examples 1-3 and the substances promoting keratinocyte proliferation in Comparative Examples 1-3 on relative migration distance.
[0085] Solvent control Comparative Example 1 Comparative Example 2 Example 1 Example 2 Example 3 Comparative Example 3 Solvent control / 0.0422 0.0238 0.0037 0.0016 0.0006 0.0391 Comparative Example 1 0.0422 / 0.0318 0.0267 0.0294 0.0093 0.0428 Comparative Example 2 0.0238 0.0318 / 0.0349 0.0216 0.0096 0.0681 Example 1 0.0037 0.0267 0.0349 / 0.0395 0.01 0.0392 Example 2 0.0016 0.0294 0.0216 0.0395 / 0.0232 0.0168 Example 3 0.0006 0.0093 0.0096 0.0100 0.0232 / 0.0086 Comparative Example 3 0.0391 0.0428 0.0681 0.0392 0.0168 0.0086 /
[0086] Table 3. Effects of the compositions promoting keratinocyte proliferation in Examples 1-3 and the substances promoting keratinocyte proliferation in Comparative Examples 1-3 on cell number and cell viability.
[0087]
[0088]
[0089] Note: When performing statistical analysis using the t-test method, the significance of each sample group compared with the solvent control group is indicated by *, p-value < 0.05 indicates *, and p-value < 0.01 indicates **.
[0090] Table 4. P-values (cell counts after 36 hours) between the compositions promoting keratinocyte proliferation in Examples 1-3 and the substances promoting keratinocyte proliferation in Comparative Examples 1-3 on cell number.
[0091] Solvent control Comparative Example 1 Comparative Example 2 Example 1 Example 2 Example 3 Comparative Example 3 Solvent control / 0.043044 0.024276 0.003774 0.001632 0.000612 0.039882 Comparative Example 1 0.043044 / 0.032436 0.027234 0.029988 0.009486 0.043656 Comparative Example 2 0.024276 0.032436 / 0.035598 0.022032 0.009792 0.069462 Example 1 0.003774 0.027234 0.035598 / 0.04029 0.0102 0.039984 Example 2 0.001632 0.029988 0.022032 0.04029 / 0.023664 0.017136 Example 3 0.000612 0.009486 0.009792 0.01021 0.023664 / 0.008772 Comparative Example 3 0.039882 0.043656 0.069462 0.039984 0.017136 0.008772 /
[0092] Table 5. P-values (cell viability after 36 h) between the compositions promoting keratinocyte proliferation in Examples 1-3 and the substances promoting keratinocyte proliferation in Comparative Examples 1-3 on cell viability.
[0093] Solvent control Comparative Example 1 Comparative Example 2 Example 1 Example 2 Example 3 Comparative Example 3 Solvent control / 0.042183 0.02379 0.003699 0.001599 0.0006 0.039084 Comparative Example 1 0.042183 / 0.031787 0.026689 0.029388 0.009296 0.042783 Comparative Example 2 0.02379 0.031787 / 0.034886 0.021591 0.009596 0.068073 Example 1 0.003699 0.026689 0.034886 / 0.039484 0.009996 0.039184 Example 2 0.001599 0.029388 0.021591 0.039484 / 0.023191 0.016793 Example 3 0.0006 0.009296 0.009596 0.009996 0.023191 / 0.008597 Comparative Example 3 0.039084 0.042783 0.068073 0.039184 0.016793 0.008597 /
[0094] The above embodiments are preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the above embodiments. Any changes, modifications, substitutions, combinations, or simplifications made without departing from the spirit and principle of the present invention shall be considered equivalent substitutions and shall be included within the protection scope of the present invention.
Claims
1. A composition that promotes keratinocyte proliferation, characterized in that, The composition consists of ergothioneine, oligopeptide-1 and active ingredient A; The active ingredient A is composed of the following components in weight percentage: sodium chloride 1.75%, sodium dihydrogen phosphate 0.55%, 1,2-hexanediol 0.375%, fibronectin 0.1%, serum albumin 0.05%, polysorbate-80 0.05%, capryloyl hydroxamic acid 0.05%, ethylhexylglycerin 0.05%, glyceryl caprylate 0.025%, and water 97%. The mass ratio of ergothioneine, oligopeptide-1 and active ingredient A is 1:(17 / 3 to 17):(8 / 3 to 10).
2. The method for preparing the composition according to claim 1, wherein ergothioneine, oligopeptide-1 and active ingredient A are mixed.
3. The use of the composition according to claim 1 in the preparation of a product, characterized in that: The products are selected from reagents, kits, culture media, skin care products, and pharmaceuticals; The reagents, kits, and culture media are used to promote the proliferation of keratinocytes; The skin care products are selected from scalp care products, body care products, and cosmetics; The drug is used for wound repair.
4. A product comprising the composition of claim 1.
5. The product according to claim 4, characterized in that: The products are selected from reagents, kits, culture media, skin care products, and pharmaceuticals; When the product is a culture medium, the product further comprises at least one of the following: glutamine, HEPES buffer, non-essential amino acids, epidermal growth factor, and basal culture medium.
6. The product according to claim 4, characterized in that: When the product is a skin care product or a medicine, the product also contains excipients; The excipients are selected from at least one of the following: humectants, thickeners, emulsifiers, gelling agents, preservatives, antioxidants, soothing agents, pH regulators, skin moisturizers, chelating agents, fragrances, and water.
7. A method for culturing keratinocytes, comprising the step of culturing cells using the composition of claim 1 and / or the culture medium of claim 5.